Dr. Bachar Dergham, MD

Hematology & Oncology Cleveland, OH Male
NPI: 1013016930
Total Payments
$456,653
2024 Payments
$72,008
Companies
34
Transactions
399
Medicare Patients
1,687
Medicare Billing
$148,908

Payment Breakdown by Category

Other$322,947 (70.7%)
Travel$74,681 (16.4%)
Consulting$45,952 (10.1%)
Food & Beverage$13,004 (2.8%)
Education$68.01 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $318,397 93 69.7%
Travel and Lodging $74,681 147 16.4%
Consulting Fee $45,952 20 10.1%
Food and Beverage $13,004 135 2.8%
Honoraria $4,550 1 1.0%
Education $68.01 3 0.0%

Top Paying Companies

Company Total Records Latest Year
Genentech USA, Inc. $173,197 134 $0 (2023)
BeiGene USA, Inc. $83,762 59 $0 (2024)
Pharmacyclics LLC, An AbbVie Company $71,181 54 $0 (2023)
Janssen Biotech, Inc. $28,777 30 $0 (2024)
Millennium Pharmaceuticals, Inc. $20,147 16 $0 (2017)
Takeda Pharmaceuticals U.S.A., Inc. $15,139 12 $0 (2018)
Kite Pharma, Inc. $14,244 20 $0 (2023)
E.R. Squibb & Sons, L.L.C. $11,236 13 $0 (2024)
Bayer HealthCare Pharmaceuticals Inc. $10,932 7 $0 (2018)
Novartis Pharmaceuticals Corporation $6,170 7 $0 (2019)

Payment History by Year

Year Amount Transactions Top Company
2024 $72,008 52 BeiGene USA, Inc. ($55,988)
2023 $94,107 96 BeiGene USA, Inc. ($27,773)
2022 $76,170 61 Genentech USA, Inc. ($33,028)
2021 $34,904 27 Pharmacyclics LLC, An AbbVie Company ($14,618)
2020 $10,792 13 Kite Pharma, Inc. ($5,652)
2019 $49,594 49 Genentech USA, Inc. ($37,767)
2018 $49,912 42 Genentech USA, Inc. ($23,381)
2017 $69,165 59 Genentech USA, Inc. ($48,910)

All Payment Transactions

399 individual payment records from CMS Open Payments — Page 1 of 16

Date Company Product Nature Form Amount Type
12/14/2024 BeiGene USA, Inc. BRUKINSA (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $5,200.00 General
Category: Oncology
12/14/2024 BeiGene USA, Inc. BRUKINSA (Drug) Travel and Lodging In-kind items and services $646.95 General
Category: Oncology
12/14/2024 BeiGene USA, Inc. BRUKINSA (Drug) Travel and Lodging In-kind items and services $471.11 General
Category: Oncology
12/14/2024 BeiGene USA, Inc. BRUKINSA (Drug) Travel and Lodging Cash or cash equivalent $280.50 General
Category: Oncology
12/14/2024 BeiGene USA, Inc. BRUKINSA (Drug) Travel and Lodging Cash or cash equivalent $154.18 General
Category: Oncology
12/14/2024 BeiGene USA, Inc. BRUKINSA (Drug) Food and Beverage Cash or cash equivalent $70.00 General
Category: Oncology
12/12/2024 BeiGene USA, Inc. BRUKINSA (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $3,900.00 General
Category: Oncology
12/12/2024 BeiGene USA, Inc. BRUKINSA (Drug) Food and Beverage In-kind items and services $136.49 General
Category: Oncology
12/11/2024 BeiGene USA, Inc. BRUKINSA (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $3,900.00 General
Category: Oncology
12/11/2024 BeiGene USA, Inc. BRUKINSA (Drug) Food and Beverage In-kind items and services $127.37 General
Category: Oncology
11/14/2024 TAIHO ONCOLOGY, INC. LONSURF (Drug) Consulting Fee Cash or cash equivalent $1,130.00 General
Category: Oncology
11/13/2024 BeiGene USA, Inc. BRUKINSA (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $3,900.00 General
Category: Oncology
11/13/2024 BeiGene USA, Inc. BRUKINSA (Drug) Food and Beverage In-kind items and services $94.61 General
Category: Oncology
10/10/2024 E.R. Squibb & Sons, L.L.C. — Consulting Fee Cash or cash equivalent $600.00 General
10/02/2024 BeiGene USA, Inc. BRUKINSA (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $5,200.00 General
Category: Oncology
10/02/2024 BeiGene USA, Inc. BRUKINSA (Drug) Travel and Lodging In-kind items and services $1,090.67 General
Category: Oncology
10/02/2024 BeiGene USA, Inc. BRUKINSA (Drug) Food and Beverage In-kind items and services $129.12 General
Category: Oncology
09/19/2024 BeiGene USA, Inc. BRUKINSA (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $5,200.00 General
Category: Oncology
09/19/2024 BeiGene USA, Inc. BRUKINSA (Drug) Travel and Lodging In-kind items and services $671.95 General
Category: Oncology
09/19/2024 BeiGene USA, Inc. BRUKINSA (Drug) Travel and Lodging In-kind items and services $519.00 General
Category: Oncology
09/19/2024 BeiGene USA, Inc. BRUKINSA (Drug) Travel and Lodging In-kind items and services $283.45 General
Category: Oncology
09/19/2024 BeiGene USA, Inc. BRUKINSA (Drug) Food and Beverage In-kind items and services $130.00 General
Category: Oncology
09/19/2024 BeiGene USA, Inc. BRUKINSA (Drug) Travel and Lodging Cash or cash equivalent $124.81 General
Category: Oncology
08/20/2024 BeiGene USA, Inc. BRUKINSA (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $1,950.00 General
Category: Oncology
06/18/2024 E.R. Squibb & Sons, L.L.C. — Consulting Fee Cash or cash equivalent $600.00 General
123…16»

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 6 428 703 $266,013 $41,511
2022 6 405 631 $222,784 $38,962
2021 7 396 591 $195,803 $36,088
2020 7 458 684 $203,532 $32,348
Total Patients
1,687
Total Services
2,609
Medicare Billing
$148,908
Procedure Codes
26

All Medicare Procedures & Services

26 procedure records from CMS Medicare Utilization — Page 1 of 2

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99213 Established patient office or other outpatient visit, 20-29 minutes Office 2023 207 355 $96,560 $15,856 16.4%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2023 112 229 $95,951 $15,761 16.4%
99204 New patient office or other outpatient visit, 45-59 minutes Office 2023 35 35 $27,153 $3,100 11.4%
99443 Telephone medical discussion with physician, 21-30 minutes Office 2023 35 45 $12,513 $2,771 22.1%
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes Facility 2023 23 23 $24,380 $2,306 9.5%
99215 Established patient office or other outpatient visit, 40-54 minutes Office 2023 16 16 $9,456 $1,718 18.2%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2022 109 213 $81,153 $14,745 18.2%
99213 Established patient office or other outpatient visit, 20-29 minutes Office 2022 197 316 $78,052 $14,159 18.1%
99204 New patient office or other outpatient visit, 45-59 minutes Office 2022 45 45 $32,056 $4,609 14.4%
99215 Established patient office or other outpatient visit, 40-54 minutes Office 2022 22 23 $12,351 $2,504 20.3%
99222 Initial hospital inpatient care per day, typically 50 minutes Facility 2022 15 15 $14,460 $1,575 10.9%
99443 Telephone medical discussion with physician, 21-30 minutes Office 2022 17 19 $4,712 $1,371 29.1%
99214 Established patient outpatient visit, total time 30-39 minutes Office 2021 106 182 $67,690 $13,185 19.5%
99213 Established patient outpatient visit, total time 20-29 minutes Office 2021 164 266 $63,840 $11,605 18.2%
99204 New patient outpatient visit, total time 45-59 minutes Office 2021 49 49 $30,120 $4,636 15.4%
99215 Established patient outpatient visit, total time 40-54 minutes Office 2021 26 33 $17,193 $3,544 20.6%
99222 Initial hospital inpatient care, typically 50 minutes per day Facility 2021 13 13 $10,468 $1,415 13.5%
99442 Physician telephone patient service, 11-20 minutes of medical discussion Office 2021 25 31 $5,115 $1,390 27.2%
99441 Physician telephone patient service, 5-10 minutes of medical discussion Office 2021 13 17 $1,377 $313.06 22.7%
99213 Established patient office or other outpatient visit, typically 15 minutes Office 2020 216 359 $83,647 $12,285 14.7%
99214 Established patient office or other outpatient, visit typically 25 minutes Office 2020 95 165 $59,235 $9,946 16.8%
99204 New patient office or other outpatient visit, typically 45 minutes Office 2020 38 38 $20,996 $3,342 15.9%
99215 Established patient office or other outpatient, visit typically 40 minutes Office 2020 32 39 $19,734 $3,031 15.4%
99222 Initial hospital inpatient care, typically 50 minutes per day Facility 2020 15 15 $11,160 $1,637 14.7%
99442 Physician telephone patient service, 11-20 minutes of medical discussion Office 2020 35 41 $6,765 $1,579 23.3%
12»

About Dr. Bachar Dergham, MD

Dr. Bachar Dergham, MD is a Hematology & Oncology healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013016930.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bachar Dergham, MD has received a total of $456,653 in payments from pharmaceutical and medical device companies, with $72,008 received in 2024. These payments were reported across 399 transactions from 34 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($318,397).

As a Medicare-enrolled provider, Dergham has provided services to 1,687 Medicare beneficiaries, totaling 2,609 services with total Medicare billing of $148,908. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.

Practice Information

  • Specialty Hematology & Oncology
  • Location Cleveland, OH
  • Active Since 09/21/2006
  • Last Updated 01/30/2008
  • Taxonomy Code 207RH0003X
  • Entity Type Individual
  • NPI Number 1013016930

Products in Payments

  • TECENTRIQ (Biological) $111,169
  • IMBRUVICA (Drug) $99,284
  • BRUKINSA (Drug) $82,787
  • NINLARO (Drug) $35,286
  • Avastin (Biological) $20,116
  • Tecentriq (Biological) $16,645
  • Alecensa (Biological) $14,669
  • Yescarta (Drug) $11,944
  • Aliqopa (Drug) $10,932
  • ROZLYTREK (Biological) $10,073
  • OPDIVO (Biological) $8,236
  • KISQALI (Drug) $4,932
  • Optune Lua (NovoTTF-200T) (Device) $4,550
  • Luspatercept (Drug) $4,136
  • Reblozyl (Drug) $3,380
  • CALQUENCE (Drug) $2,800
  • Tecartus (Drug) $2,300
  • REBLOZYL (Biological) $1,539
  • LONSURF (Drug) $1,130
  • KEYTRUDA (Biological) $953.87

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Hematology & Oncology Doctors in Cleveland

Hillard Lazarus, Md, MD

Hematology & Oncology — Payments: $2.5M

Hematology & Oncology $2.5M

Jorge Garcia, Md, MD

Hematology & Oncology — Payments: $765,093

Hematology & Oncology $765,093

Ronald Bukowski, Md, MD

Hematology & Oncology — Payments: $744,876

Hematology & Oncology $744,876

Balazs Halmos, Md, MD

Hematology & Oncology — Payments: $548,525

Hematology & Oncology $548,525

Dr. Dale Shepard, M.d., Ph.d, M.D., PH.D

Hematology & Oncology — Payments: $481,414

Hematology & Oncology $481,414

Dr. Brian Hill, M.d., Ph.d, M.D., PH.D

Hematology & Oncology — Payments: $334,203

Hematology & Oncology $334,203